Pre-AIDS mortality from natural causes associated with HIV disease progression: Evidence from the European Seroconverter Study among injecting drug users

AIDS

Volumn 11, Issue 14, 1997, Pages 1747-1756

  Prins, Maria ^a   Aguado, Ildefonso Hernández ^b   Brettle, Raymond P ^c   Robertson, J Roy ^d   Broers, Barbara ^e   Carré, Nicolas ^f   Goldberg, David J ^g   Zangerle, Robert ^h   Coutinho, Roel A ^a   Van Den Hoek, Anneke ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b UNIVERSITY OF ALICANTE   (Spain)

^c CITY HOSPITAL   (United Kingdom)

^d Edinburgh Drug Addiction Study   (United Kingdom)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f BICÊTRE HOSPITAL   (France)

^g RUCHILL HOSPITAL   (United Kingdom)

^h UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

HIV disease progression; Injecting drug users; Pre AIDS mortality

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; DISEASE COURSE; DRUG OVERDOSE; EUROPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; SEROCONVERSION; SUICIDE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; EUROPE; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 9844224474     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199714000-00012     Document Type: Article

References (36)

1. Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F: Mortality of intravenous drug users in Rome: a cohort study. Am J Public Health 1991, 81:1307-1310
2. Zaccarelli M, Gattari P, Rezza G, et al.: Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 1994, 8:345-350.
3. Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P: Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol 1993, 22:315-320.
4. Goedert JJ, Pizza G, Gritti FM, et al.: Mortality among drug users in the AIDS era. Int J Epidemiol 1995, 24:1204-1210.
5. Selwyn PA, Hartel D, Wasserman W, Drucker E: Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City Methadone Maintenance Program. Am J Public Health 1989, 79:1358-1362.
6. Stoneburner RL, Des Jarlais DC, Benezra D, et al.: A larger spectrum of severe HIV-1 related disease in intravenous drug users in New York City. Science 1988, 242:916-919.
7. Galli M, Musicco M, COMAT Study Group: Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection. AIDS 1994, 8:1457-1463.
8. Orti RM, Domingo-Salvany A, Muñoz A, Macfarlane D, Suelves JM, Antó JM: Mortality trends in a cohort of opiate addicts, Catalonia, Spain. Int J Epidemiol 1996, 25:545-553.
9. Des Jarlais DC, Friedman SR, Stoneburner RL: HIV infection and intravenous drug use: critical issues in transmission dynamics, infection outcomes, and prevention. Rev Infect Dis 1988, 10:151-158.
10. Van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Bax JS, Coutinho RA: Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 1996, 143:380-391.
11. Selwyn PA, Alcabes P, Hartel D, et al.: Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992, 327:1697-1703.
12. Hernández-Aguado I, Bolumar F: Determinants of HIV-1 infection in intravenous drug users in Valencia, Spain, 1987-1991. Int J Epidemiol 1993, 22:537-542.
13. Skidmore CA, Robertson JR, Robertson AA, Elton RA: After the epidemic: follow up study of HIV seroprevalence and changing patterns of drug use. BMJ 1990, 300:219-223.
14. Brettle RP, Bisset K, Burns S, et al.: Human immunodeficiency virus and drug misuse: the Edinburgh experience. BMI 1987, 295:421-424.
15. van den Hoek JAR, Coutinho RA, van Haastrecht HJA, van Zadelhoff AW, Goudsmit J: Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988, 2:55-60.
16. Ledergerber B, Von Overbeck J, Egger M, Luthy R: The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994, 39:387-394.
17. Carré N, Deveau C, Belanger F, et al.: Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. AIDS 1994, 8:797-802.
18. Goldberg DJ, Emslie JA, Smyth W, Reid D: A system for surveillance of voluntary HIV testing: results of the first 2 years 1989-1990. AIDS 1992, 6:495-500.
19. Zangerle R, Fuchs D, Rossler H, et al.: Trends in HIV infection among intravenous drug users in Innsbruck, Austria. J Acquir Immune Defic Syndr 1992, 5:865-871.
20. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36:1S-15S.
21. Jongbloed G: The Iterative Convex Minorant Algorithm for Nonparametric Estimation. Technical Report. Delft: University of Technology; 1995.
22. Groeneboom P, Wellner JA: Information Bounds and Non-Parametric Maximum Likelihood Estimation. Berlin: Birkhäuser Verlag; 1992.
23. Prins M, Veugelers PJ, European Seroconverter Study and the Tricontinental Seroconverter Study: Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. AIDS 1997, 11:621-631.
24. Andersen PK, Borgan O, Gill RD, Keiding N: Statistical Models Based on Counting Processes. New York: Springer; 1993.
25. Anonymous: EGRET User's Manual. Seattle: Statistics and Epidemiology Research, Corp.; 1992.
26. Phillips AN, Pezzotti P, Cozzi Lepri A, Rezza G, Italian Seroconversion Study: CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS 1994, 8:1299-1305.
27. Shi M, Taylor JMG, Currier RJ, et al.: Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. J Acquir Immune Defic. Syndr Hum Retrovirol 1996, 12:309-316.
28. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA: Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts. Am J Epidemiol 1993, 138:870-878.
29. van Haastrecht HJA, Mientjes GHC, van den Hoek JAK, Coutinho RA: Death from suicide and overdose among drug injectors after disclosure of first HIV test result. AIDS 1994, 8:1721-1725.
30. van Ameijden EJC, Vlahov D, van den Hoek JAR, Flynn C, Coutinho RA: Pre-AIDS mortality and morbidity among injection drug users in cohort studies in Amsterdam and Baltimore. XI International Conference on AIDS. Vancouver, July 1996 |abstract ThC220|.
31. Jones ME, Brettle RP, Busuttil A, Inglis MH, Bell JE, Willocks L: Sudden death in HIV-infected drug users. Presumptive overdose in an HIV-positive narcotic addict. J Infect 1993 27:79-81.
32. Hammersley R, Cassidy MT, Oliver J: Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992. Addiction 1995, 90:959 965.
33. Frischer M, Goldberg D, Rahman M, Berney L: Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 1997, 92:419-427.
34. Ancelle-Park RA: European AIDS definition. Lancet 1992, 339:671.
35. Darby SC, Twart DW, Giangrande PLF, Spooner RJD, Rizza CR CR: Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996, 347:1573-1579.
36. Mulder DW, Nunn AJ, Kamali A, Nakiyingi J, Wagner HU, Kengeya-Kayondo JF: Two-year HIV-1-associated mortality in a Ugandan rural population. Lancet 1994, 343:1021-1023.